<- Go Home
CERo Therapeutics Holdings, Inc.
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
Market Cap
$10.0M
Volume
21.1K
Cash and Equivalents
$5.2M
EBITDA
-$16.4M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$895.40
52 Week Low
$6.71
Dividend
N/A
Price / Book Value
-0.78
Price / Earnings
-0.03
Price / Tangible Book Value
-0.78
Enterprise Value
$8.6M
Enterprise Value / EBITDA
-0.58
Operating Income
-$16.8M
Return on Equity
515.76%
Return on Assets
-122.86
Cash and Short Term Investments
$5.2M
Debt
$1.4M
Equity
-$329.4K
Revenue
N/A
Unlevered FCF
-$11.2M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium